Shrinking Waveforms on Electrocardiograms Predict Worsening Health and Death of Hospitalized COVID-19 and Influenza Patients
Spotting changes in the heart’s electrical activity may prompt more-aggressive treatment and monitoring
Specific and dynamic changes on electrocardiograms (EKGs) of hospitalized patients with COVID-19 or influenza can help predict a timeframe for worsening health and death, according to a new Mount Sinai study. The work, published in the September 24 online issue of the American Journal of Cardiology, shows that shrinking waveforms on these tests can be used to help better identify high-risk patients and provide them more aggressive monitoring and treatment.
“Our study shows diminished waveforms on EKGs over the course of COVID-19 illness can be an important tool for health care workers caring for these patients, allowing them to catch rapid clinical changes over their hospital stay and intervene more quickly. With COVID-19 cases and hospitalizations continuing to rise again, EKGs may be helpful for hospitals to use when caring for these patients before their condition gets dramatically worse,” says senior author Joshua Lampert, MD, Cardiac Electrophysiology fellow at The Mount Sinai Hospital. “This is particularly useful in overwhelmed systems, as there is no wait for blood work to return and this test can be performed by the majority of health care personnel. Additionally, the EKG can be done at the time of other bedside patient care, eliminating the potential exposure of another health care worker to COVID-19.”
An EKG is a noninvasive test that records the electrical activity of the heart. It is widely used for diagnosing cardiovascular disease and arrhythmia, or abnormal heart rhythm. Small patches called electrodes are placed on the arms, legs, and chest, and connected by wires to a machine that turns the heart’s electrical signals into wavy lines.
Researchers did a retrospective analysis of EKGs on 140 patients hospitalized with COVID-19 across the Mount Sinai Health System in New York City between March 7 and April 12, 2020, and compared them with 281 EKGs from patients with laboratory-confirmed influenza A or influenza B admitted to The Mount Sinai Hospital between January 2, 2017, and January 5, 2020.
The researchers looked at three EKG time points for each patient: a baseline scan done within a year prior to COVID-19 or influenza hospitalization (and available in Mount Sinai’s records), a scan taken at hospital admission, and follow-up EKGs performed during hospitalization.
They manually measured QRS waveform height—a measure of the electrical activity of the ventricles, the major chambers of the heart—on all electrocardiograms; changes in this electrical activity could be a sign that the ventricles are failing. The researchers analyzed follow-up EKGs after hospital admission and analyzed changes in the waveforms according to a set of criteria they developed called LoQRS amplitude (LoQRS) to identify a shrinkage of the electrical signal on the EKG. LoQRS was defined by QRS amplitude measuring less than 5mm measured from the arms and legs or less than 10mm when measured on the chest wall as well as a relative reduction in waveform height in either location by at least 50 percent.
Fifty-two COVID-19 patients in the study did not survive, and the analysis shows 74 percent of those patients had LoQRS. Their EKG QRS waveforms became smaller roughly 5.3 days into their hospital admission and they died approximately two days after the first abnormal EKG was found.
Out of the 281 influenza patients studied, LoQRS was identified in 11 percent of them. Seventeen influenza patients died, and LoQRS was present in 39 percent of these cases. Influenza patients met LoQRS criteria a median of 55 days into their hospital admission, and the median time to death was six days from when LoQRS was identified. Overall, these results show influenza patients followed a less virulent course of illness when compared to COVID-19 patients.
“When it comes to caring for COVID-19 patients, our findings suggest it may be beneficial not only for health care providers to check an EKG when the patient first arrives at the hospital, but also follow-up EKGs during their hospital stay to assess for LoQRS, particularly if the patient has not made profound clinical progress. If LoQRS is present, the team may want to consider escalating medical therapy or transferring the patient to a highly monitored setting such as an intensive care unit (ICU) in anticipation of declining health,” adds Dr. Lampert.
Figure:
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
Mount Sinai Scientists Uncover Link Between Influenza and Heart Disease
Feb 09, 2026 View All Press Releases
Scientists Develop a Smarter mRNA Therapy That Knows Which Cells to Target
Dec 15, 2025 View All Press Releases